Glypican 3

GPC3
Identifiers
Aliases	GPC3, DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, SGBS, SGBS1, Glypican 3
External IDs	OMIM: 300037; MGI: 104903; HomoloGene: 20944; GeneCards: GPC3; OMA:GPC3 - orthologs
Gene location (Human) Chr. X chromosome (human)[1] Band Xq26.2 Start 133,535,745 bp[1] End 133,987,100 bp[1]
Gene location (Mouse) Chr. X chromosome (mouse)[2] Band X|X A5 Start 51,361,303 bp[2] End 51,702,827 bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in upper lobe of left lung right lung tibial nerve placenta subcutaneous adipose tissue anterior pituitary cartilage tissue right coronary artery lower lobe of lung left coronary artery Top expressed in belly cord abdominal wall mandibular prominence tail of embryo genital tubercle maxillary prominence yolk sac efferent ductule Gonadal ridge hand More reference expression data BioGPS More reference expression data
Gene ontology Molecular function peptidase inhibitor activity protein binding peptidyl-dipeptidase inhibitor activity heparan sulfate proteoglycan binding Cellular component membrane anchored component of plasma membrane plasma membrane integral component of plasma membrane extracellular region lysosomal lumen Golgi lumen anchored component of membrane lysosome extracellular space endoplasmic reticulum lumen intrinsic component of plasma membrane collagen-containing extracellular matrix Biological process body morphogenesis positive regulation of glucose import bone mineralization negative regulation of peptidase activity negative regulation of growth negative regulation of smoothened signaling pathway positive regulation of protein catabolic process positive regulation of smoothened signaling pathway cell proliferation involved in metanephros development lung development kidney development osteoclast differentiation anatomical structure morphogenesis mesenchymal cell proliferation involved in ureteric bud development mesonephric duct morphogenesis coronary vasculature development retinoid metabolic process cell proliferation involved in kidney development positive regulation of endocytosis branching involved in ureteric bud morphogenesis glycosaminoglycan catabolic process glycosaminoglycan biosynthetic process negative regulation of epithelial cell proliferation positive regulation of BMP signaling pathway animal organ morphogenesis regulation of growth positive regulation of Wnt signaling pathway, planar cell polarity pathway anterior/posterior axis specification negative regulation of canonical Wnt signaling pathway negative regulation of cell population proliferation embryonic hindlimb morphogenesis post-translational protein modification regulation of signal transduction response to bacterium Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 2719 14734 Ensembl ENSG00000147257 ENSMUSG00000055653 UniProt P51654 Q8CFZ4 RefSeq (mRNA) NM_004484 NM_001164617 NM_001164618 NM_001164619 NM_016697 RefSeq (protein) NP_001158089 NP_001158090 NP_001158091 NP_004475 NP_004475.1 NP_057906 Location (UCSC) Chr X: 133.54 – 133.99 Mb Chr X: 51.36 – 51.7 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Glypican-3 is a protein that, in humans, is encoded by the GPC3 gene.^[5][6][7][8] The GPC3 gene is located on human X chromosome (Xq26) where the most common gene (Isoform 2, GenBank Accession No.: NP_004475) encodes a 70-kDa core protein with 580 amino acids.^[9] Three variants have been detected that encode alternatively spliced forms termed Isoforms 1 (NP_001158089), Isoform 3 (NP_001158090) and Isoform 4 (NP_001158091).^[9]

Structure and function

The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa.^[9] Six glypicans (GPC1-6) have been identified in mammals. Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation.^[7] GPC3 has been found to regulate Wnt/β-catenin and Yap signaling pathways.^{[9][10][11][12][13][14][15][16]} GPC3 interacts with both Wnt and frizzled (FZD) to form a complex and triggers downstream signaling.^[11][17] The core protein of GPC3 may serve as a co-receptor or a receiver for Wnt. A cysteine-rich domain at the N-lobe of GPC3 has been identified as a hydrophobic groove that interacts with Wnt3a.^[17] Blocking the Wnt binding domain on GPC3 using the HN3 single domain antibody can inhibit Wnt activation.^[17] Wnt also recognizes a heparan sulfate structure on GPC3 , which contains IdoA2S and GlcNS6S, and that the 3-O-sulfation in GlcNS6S3S significantly enhances the binding of Wnt to heparan sulfate.^[10] GPC3 also modulates Yap signaling.^[12] It might interact with FAT1 on the cell surface.^[15]

Disease linkage

Deletion mutations in this gene are associated with Simpson–Golabi–Behmel syndrome.^[5]

Diagnostic utility

Glypican 3 immunostaining has utility for differentiating hepatocellular carcinoma (HCC)^[18] and dysplastic changes in cirrhotic livers; HCC stains with glypican 3, while liver with dysplastic changes and/or cirrhotic changes does not.^[19] Using the YP7 murine monoclonal antibody, GPC3 protein expression is found in HCC, not in normal liver and cholangiocarcinoma.^[20] The YP7 murine antibody has been humanized and named as 'hYP7'.^[21] GPC3 is also expressed to a lesser degree in melanoma, ovarian clear-cell carcinomas, yolk sac tumors, neuroblastoma, hepatoblastoma, Wilms' tumor cells, and other tumors.^[9] However, the significance of GPC3 as a diagnostic tool for human tumors other than HCC is unclear.^{[citation needed]}

Therapeutic potential

To validate GPC3 as a therapeutic target in liver cancer, the anti-GPC3 therapeutic antibodies GC33,^[22] YP7,^[20] HN3^[12] and HS20^[13][23] have been made and widely tested. The laboratory of Mitchell Ho at the National Cancer Institute, NIH (Bethesda, Maryland, US) has generated YP7 and other murine monoclonal antibodies that recognize the C-lobe of GPC3 by hybridoma technology.^[20] These antibodies have been humanized (e.g. hYP7) via antibody engineering for clinical applications.^[21] The Ho lab has also identified the human single-domain antibody ('human nanobody') HN3^[12] targeting the N-lobe of GPC3 ^[17] and the human monoclonal antibody HS20^[13][24] targeting the heparan sulfate chains on GPC3 by phage display technology. Both HN3 and HS20 antibodies inhibit Wnt signaling in liver cancer cells . The immunotoxins based on HN3,^[14][25][26] the antibody-drug conjugates based on hYP7^[27] and the T-cell engaging bispecific antibodies derived from YP7^[28][29] and GC33,^[30] have been developed for treating liver cancer. The chimeric antigen receptor (CAR) T cell immunotherapies based on GC33,^[31] hYP7^[32][33] and HN3^[34] are being developed at various stages for treating liver cancer. In mice with xenograft or orthoptic liver tumors, CAR (hYP7) T cells can eliminate GPC3-positive cancer cells, by inducing perforin- and granzyme-mediated cell death and reducing Wnt signaling in tumor cells.^[33] CAR (hYP7) T cells are being evaluated at a clinical trial at the NIH.^[35]

See also

• Glypican

References

Further reading

External links

• GeneReviews/NIH/NCBI/UW entry on Simpson-Golabi-Behmel Syndrome